Relapsed Refractory Multiple Myeloma (RRMM) Latest Advances
Find the Latest Research About Relapsed Refractory Multiple Myeloma (RRMM)
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 223 publications
Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.
Journal: Future oncology (London, England)
Published: August 30, 2026
Bispecific Antibodies in Multiple Myeloma: A Concise Review of Current Treatments.
Journal: Cancer investigation
Published: June 21, 2026
Tympanic Membrane Involvement of Multiple Myeloma: Report of a Case.
Journal: Hematology reports
Published: May 14, 2026
Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.
Journal: Transplantation and cellular therapy
Published: February 12, 2026
Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives.
Journal: European journal of haematology
Published: January 19, 2026
Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series.
Journal: British journal of haematology
Published: January 17, 2026
Analyzing Real-World Infection Risk in Multiple Myeloma Patients Receiving Teclistamab.
Journal: Current oncology (Toronto, Ont.)
Published: January 10, 2026
Pomalidomide re-exposure after drug-related severe hypothyroidism: a case report.
Journal: Annals of hematology
Published: December 17, 2025
Last Updated: 09/26/2026